Sanofi Pasteur spent 20 years and $1.5 billion researching its dengue fever vaccine, Dengvaxia, and now it's looking to maximize the vaccine's impact. To do that, the French pharma's vaccine division is working with regulators and health officials to identify implementation strategies, program head Guillaume Leroy told FierceVaccines.
Joining a wave of companies racing in the HIV vaccines space, Aelix Therapeutics announced a $12.7 million Series A round this week--and funding from Johnson & Johnson Innovation--to support work on its therapeutic HIV vaccine candidate.
Oxfordshire, U.K.-based Midatech has licensed its gold nanoparticle technology to fellow U.K. biotech Emergex Vaccines in an exclusive deal. Emergex will apply the technology to developing and commercializing vaccines against infectious diseases.
Merck and GlaxoSmithKline have spent years working to build the market for their HPV vaccines, and a new study may demonstrate one factor that has hindered their efforts.
In December 2015, the China FDA approved the first vaccine against the virus that causes hand, foot and mouth disease, a common infectious disease often found in children. But competition was not far behind: the agency approved a second vaccine against the virus on Monday, this one developed by Sinovac.
The Philippines' FDA approved Sanofi's first-of-its-kind dengue fever vaccine, Dengvaxia, on Tuesday. And on the same day, India's Economic Times reported that the government there is exploring opportunities to accelerate marketing authorization for the vaccine, considering exempting it from large local clinical trials.
Days after Sanofi received its first approval in Mexico for its pioneering dengue fever vaccine, it's said to be in discussions to bring the jab to India following a successful trial on an adult population there.
Infectious diseases in China killed 1,639 people in November, according to a report by state-run news agency Xinhua, which also said National Health and Family Planning Commission figures showed 519,285 people tested positive for infectious diseases.
A team from the Yale Cancer Center has devised a novel dosing schedule for flu vaccines aimed at increasing protection for cancer patients who are at a higher risk of contracting the viral infection.
Seeking a dengue fever vaccine that can offer broad protection in a short time, the U.S. Army has awarded Hawaii Biotech a Phase I contract to support the company's work against the "potentially mission-aborting" disease, according to a press release.